Faiza Baameur Hancock

Faiza Baameur Hancock

Auto-generated profile, based on publicly available information

Faiza Baameur Hancock

Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
CFChristopher P. Fagundes
Christopher P. Fagundes
KMKyle W. Murdock
Kyle W. Murdock
ALAngie LeRoy
Angie LeRoy
FBFaiza Baameur
Faiza Baameur
JTJulian F. Thayer
Julian F. Thayer
CHCobi Heijnen
Cobi Heijnen

13 August 2025 in Cancer Research
Verified
Journal Article
Closed access
ARAmanda L. Rinkenbaugh
Amanda L. Rinkenbaugh
YQYuan Qi
Yuan Qi
SCShirong Cai
Shirong Cai
JSJiansu Shao
Jiansu Shao
FHFaiza Baameur Hancock
Faiza Baameur Hancock
HPHelen Piwnica-Worms
Helen Piwnica-Worms
Triple-negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogeneity characteristic of TNBC. To that end, we established a biobank of 92 orthotopic patient-derived xenograft (PDX) models of TNBC from the tumors of 75 patients enrolled in A Robust TNBC Evaluation fraMework to Improve Survival clinical trial (ARTEMIS, NCT02276443), including 12 longitudinal sets generated from serial patient biopsies collected throughout NACT treatment and from metastatic disease. Models were established from both chemosensitive and chemoresistant tumors, and nearly 30% of the PDX models were capable of metastasizing to the lungs. Comprehensive molecular profiling demonstrated conservation of genomes and transcriptomes between patient and corresponding PDX tumors, with representation of all major transcriptional subtypes. Transcriptional changes observed in the longitudinal PDX models highlighted dysregulation in pathways associated with DNA integrity, extracellular matrix interactions, the ubiquitin–proteasome system, epigenetics, and inflammatory signaling. These alterations revealed a complex network of adaptations associated with chemoresistance. Overall, this PDX biobank provides a valuable tool for tackling the most pressing issues facing the clinical management of TNBC. Significance: The development of a patient-derived xenograft biobank that comprehensively captures the genomic and transcriptional diversity of triple-negative breast cancer promises to be a robust resource to investigate and overcome chemoresistance and metastasis.

3 April 2026 in Science Advances
Verified
Journal Article
Open access
YJYan Jiang
Yan Jiang
NANoor M. Abdulkareem
Noor M. Abdulkareem
ARAmanda L. Rinkenbaugh
Amanda L. Rinkenbaugh
YQYuan Qi
Yuan Qi
SWSteven W. Wall
Steven W. Wall
HPHelen Piwnica-Worms
Helen Piwnica-Worms
Systemic neoadjuvant chemotherapy, often combined with immunotherapy, is the standard of care for early-stage, non–breast cancer susceptibility gene (BRCA)-mutant triple negative breast cancer (TNBC). However, up to 70% of patients retain residual disease after treatment, which is linked to recurrence and mortality within 5 years. To define mechanisms of resistance, we performed single-cell RNA sequencing on orthotopic TNBC patient-derived xenografts during a cycle of treatment with doxorubicin and cyclophosphamide (AC). Clustering identified four tumor epithelial cell populations, with basal cells enriched in residual tumors. These basal cells up-regulated C15ORF48, a paralog of the mitochondrial cytochrome c oxidase associated subunit FA4 (NDUFA4), while exhibiting reciprocal down-regulation of NDUFA4. Functionally, C15ORF48 knockdown sensitized breast cancer cells to AC, increasing reactive oxygen species (ROS) and apoptosis. Thus, the up-regulation of C15ORF48 blunts ROS accumulation and induces resistance to chemotherapy in the basal cell subpopulations. Our findings identify C15ORF48 as a potential therapeutic target for overcoming AC resistance in TNBC.



3 November 2025
Verified
Other
Open access
PDF file
ARAmanda L. Rinkenbaugh
Amanda L. Rinkenbaugh
YQYuan Qi
Yuan Qi
SCShirong Cai
Shirong Cai
JSJiansu Shao
Jiansu Shao
FHFaiza Baameur Hancock
Faiza Baameur Hancock
HPHelen Piwnica-Worms
Helen Piwnica-Worms
Inclusion of murine stromal reads in PDX model gene expression